OncoMatch/Clinical Trials/NCT07458347
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Is NCT07458347 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies KST-6051 for kras-mutant non-small cell lung cancer (nsclc).
Treatment: KST-6051 — The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Colorectal Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment
Progressed on or intolerant to standard treatment(s).
Cannot have received: RAS inhibitor
Previous or current treatment with RAS or KRAS inhibitors.
Cannot have received: KRAS inhibitor
Previous or current treatment with RAS or KRAS inhibitors.
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate liver function
Cardiac function
adequate cardiovascular function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Oncology · San Antonio, Texas
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07458347 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior RAS inhibitor, KRAS inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify